An iterative model for in vitro laboratory assessment of tamper deterrent formulations

Drug and Alcohol Dependence

Volumn 131, Issue 1-3, 2013, Pages 100-105

  Cone, Edward J ^a,b,d   Giordano, Jennifer ^c   Weingarten, Brianne ^c  

^a PINNEY ASSOCIATES   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c PURDUE PHARMA L P   (United States)

^d One Stamford Forum ^*  (United States)

Author keywords

Abuse; Abuse deterrent; Formulation; Oxycodone; Tamper

Indexed keywords

OXYCODONE; SOLVENT;

ARTICLE; CHEMICAL ANALYSIS; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG ISOLATION; DRUG PURITY; DRUG SOLUBILITY; EXTRACTION; IN VITRO STUDY; INJECTION; ITERATIVE MODEL; LABORATORY TEST; MODEL; PARTICLE SIZE; PREDICTION; PRIORITY JOURNAL; TABLET FORMULATION; TAMPER DETERRENT FORMULATION; VAPORIZATION;

CHEMISTRY, PHARMACEUTICAL; HUMANS; MODELS, CHEMICAL; OPIOID-RELATED DISORDERS; OXYCODONE; PARTICLE SIZE; SUBSTANCE-RELATED DISORDERS;

EID: 84878586947     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.12.006     Document Type: Article

References (19)

1. Chilcoat H., Coplan P., Cassidy T.A., Black R., Landau C., Budman S.H., Butler T.J. Impact on reformulated OxyContin on rates of abuse through oral and non-oral routes among individuals assessed in substance abuse treatment. College on Problems of Drug Dependence, 74th Annual Meeting 2012.
2. Comer S.D., Ashworth J.B., Sullivan M.A., Vosburg S.K., Saccone P.A., Foltin R.W. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J. Opioid Manag. 2009, 5:203-212.
3. Committee on Advancing Pain Research Care Education Board on Health Sciences Policy Relieving Pain in America; A Blueprint for Transforming Prevention, Care, Education and Research 2011, The National Academies Press, Washington.
4. Cone E.J. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend. 2006, 83(Suppl. 1):S31-S39.
5. ® Reformulation 2012, American Academy of Pain Management, Phoenix, AZ, September 20-23, 2012.
6. Food and Drug Administration Guidance for Industry; Assessment of Abuse Potential of Drugs 2010, Center for Drug Evaluation and Research, Department of Health and Human Services, Washington, DC.
7. Grudzinskas C., Balster R.L., Gorodetzky C.W., Griffiths R.R., Henningfield J.E., Johanson C.E., Mansbach R.S., McCormick C.G., Schnoll S.H., Strain E.C., Wright C. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend. 2006, 83(Suppl. 1):S77-S82.
8. Hamed E., Moe D. Development of tamper deterrent formulations: state of the pharmaceutical industry. Curr. Drug Abuse Rev. 2010, 3:139-146.
9. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream?. Curr. Rheumatol. Rep. 2008, 10:11-18.
10. Katz N.P., Adams E.H., Chilcoat H., Colucci R.D., Comer S.D., Goliber P., Grudzinskas C., Jasinski D., Lande S.D., Passik S.D., Schnoll S.H., Sellers E., Travers D., Weiss R. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin. J. Pain 2007, 23:648-660.
11. Larman C., Basili V.R. Iterative and incremental development: a brief history. Computer 2003, 36:47-56.
12. Mansbach R.S., Moore R.A. Formulation considerations for the development of medications with abuse potential. Drug Alcohol Depend. 2006, 83(Suppl. 1):S15-S22.
13. Schuster C.R. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend. 2006, 83(Suppl. 1):S8-S14.
14. ®. RADARS 6th Annual Scientific Meeting 2012.
15. Stoops W.W., Hatton K.W., Lofwall M.R., Nuzzo P.A., Walsh S.L. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl.) 2010, 212:193-203.
16. Substance Abuse and Mental Health Services, 2011. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD.
17. Substance Abuse and Mental Health Services Administration The DAWN Report: Highlights of the 2009 Drug Abuse Warning Network (DAWN) Finding on Drug-Related Emergency Department Visits 2010, Center for Behavioral Health Statistics and Quality, Rockville, MD.
18. Walden M., Nicholls F.A., Smith K.J., Tucker G.T. The effect of ethanol on the release of opioids from oral prolonged-release preparations. Drug Dev. Ind. Pharm. 2007, 33:1101-1111.
19. Young A.M., Havens J.R., Leukefeld C.G. Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct. J. 2010, 7:24.